Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

In the Media

  • January 7, 2022

InMed Pharmaceuticals (NASDAQ: INM) “Addressing The Increasing Demand For Rare Cannabinoids”

InMed’s CEO, Eric A. Adams, and BayMedica’s SVP and GM, Shane Johnson, and VP of Commercial Operations, Chris Meiering, join Tribe Public’s Webinar “Addressing the Increasing Demand for Rare Cannabinoids.”

Host John Heerdink talks to the team about which rare cannabinoids are emerging, InMed and BayMedica’s plans to launch new products to address the demand. They talk about leveraging the company’s different cannabinoid manufacturing methods to produce these rare cannabinoids and how each method will have advantages depending on the compound. They talk about the importance of being able to produce these biosynthetic rare cannabinoids at large scale – being able to take it from the “benchtop” to commercial scale, such a metric tonne quantities, if required.

In addition, they talk about how biosynthetic cannabinoid manufacturing approaches will enable access to high purity and consistent rare cannabinoids, which are impractical to extract from the plant due to their minuscule amounts in the plant.

Full Article
Source: Tribe Public

Share this post

Latest Articles

How Could a Change in Legislation Affect the Cannabinoid Industry?

InMed’s VP, Sales & Marketing, Jerry P. Griffin, talks about how a change in legislation could impact the bioidentical cannabinoid manufacturing industry. In this interview,

Read More
May 16, 2023

BayMedica’s Bioidentical Rare Cannabinoids Fill a Market Need for Large Scale Batch-to-batch Consistency

InMed’s VP, Sales & Marketing, Jerry P. Griffin, talks about how the market for bioidentical rare cannabinoids has changed over the past year. Jerry contributes

Read More
May 8, 2023

The Dales Report: InMed’s Latest Milestones Explained

InMed CEO, Eric A. Adams, joins Shadd Dales of The Dales Report to speak about InMed’s latest milestones including the latest on the Phase 2

Read More
April 19, 2023
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent